IQM to Deploy Poland’s First Superconducting Quantum Computer
24.4.2025 10:21:00 CEST | Business Wire | Press Release
The first quantum computer in Poland developed by IQM Quantum Computers, a global leader in superconducting quantum computers, will be operational at the Wrocław University of Science and Technology (WUST) in the second quarter of this year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424928607/en/
IQM Spark quantum computer
This instalment of a full-stack quantum computer marks a critical milestone in the country’s technological advancement. The 5-qubit quantum computer called “IQM Spark” will enable the university to spearhead research work mainly in the field of computer science.
The system will also be made available to researchers, doctoral candidates, and computer science students. Some of the first users who will run their programmes on the system are expected to be members of the qubit quantum computing club operating at the university.
“This is the first quantum computer in our country and Eastern Europe using low-temperature superconducting qubit technology. The system will offer students in Poland direct access to the actual quantum computer for practical programming in quantum computing. Our goal is to conduct research and educate IT specialists,” said Professor Wojciech Bożejko, Faculty of Information and Communication Technology at WUST.
Following its expansion to Poland last year with a new office, IQM has rolled out initiatives to support the country in building a sustainable quantum computing ecosystem. These include the acceleration of market adoption of quantum solutions while collaborating with key stakeholders and investing in local talent.
The Co-CEO of IQM Quantum Computers, Mikko Välimäki, highlights the significance of the system for Poland: “We are proud to deliver the nation's first quantum computer to strengthen its position as a leading hub in quantum development in Central and Eastern Europe, elevate research and have the potential to transform modern science and industry.”
The Chief Commercial Officer and Country Director for the Central and Eastern Europe (CEE) market at IQM, Sylwia Barthel de Weydenthal, added: “With Poland’s deep-rooted strengths in physics, mathematics, engineering, and computer science, Poland has the ideal foundation for nurturing local talent and fostering a new generation of scientists and engineers.”
The university plans to inaugurate the system at the Wrocław Centre for Networking and Supercomputing to mark the 30th anniversary of the Centre.
About Wrocław University of Science and Technology:
Wrocław University of Science and Technology (Wrocław Tech) was established in 1945, mainly as a result of the involvement of the academic staff of the now-defunct Technical University of Lviv and the Jan Kazimierz University in Lviv, who adapted the destroyed buildings of the German School of Technology - Technische Hochschule.
There are currently 20, 288 students, 758 people at the Doctoral School pursuing their degree programmes under the supervision of over 2, 296 academic teachers at Wrocław Tech’s 14 faculties and three branches. We also have 1,312 foreign students from over 60 countries around the world.
Each year, a number of our original technical solutions, patents, inventions, and technologies used in industry obtain patent protection. Over the past ten years alone, we have been granted 2, 822 patents, in which respect we are among the national leaders. The university has 581 educational laboratories, 407 research laboratories, and 8 accredited laboratories.
About IQM Quantum Computers:
IQM is a global leader in superconducting quantum computers. IQM provides both on-premises full-stack quantum computers and a cloud platform to access its computers. IQM customers include the leading high-performance computing centres, research labs, universities and enterprises which have full access to IQM's software and hardware. IQM has over 280 employees with offices in Colorado, Espoo, Italy, Munich, Madrid, Paris, Singapore, Tokyo, and Warsaw.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250424928607/en/
Contacts
Media contact:
Email: press@meetiqm.com
Mobile: +358504790845
www.meetiqm.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.meetiqm.com
%2F&esheet=54243055&newsitemid=20250424928607&lan=en-US&anchor=www.meetiqm.com&i
ndex=1&md5=9a111a1281aa114a31e604cae69eaeae
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press Release
Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland required for equivalent yields and logistical carbon. Digital Reef CEO Piers Slater stated "Digital Reef embrace data centre growth and environment
SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press Release
SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5% 6% Income before taxes - GAAP basis $1,019 $1,018 $1,000 0% 2% Income before taxes margin - GAAP basis 10.8% 11.4% 11.2% -57 bps -42 bps Net income attributable to SLB - GAAP basis $735 $786 $739 -6% -1% Diluted EPS - GAAP basis $0.49 $0.52 $0.50 -6% -2% Adjusted EBITDA* $2,067 $1,899 $2,061 9% - Adjusted EBITDA margin* 21.9% 21.2% 23.1% 71 bps -121 bps Pretax segment operating income* $1,576 $1,404 $1,626 12% -3% Pretax segment operating margin* 16.7% 15.6% 18.2% 104 bps -153 bps Net income attributable to SLB, excluding charges & credits* $962 $833 $1,027
EZVIZ’s Smart Entry Solutions Have Consecutively Clinched the European Product Design Award and the Golden Pin Design Award, Indicating a Shift From Home Security to Living Enjoyment23.10.2026 11:58:00 CEST | Press Release
EZVIZ’s smart lock and AI-powered doorbell remained in the spotlight after IFA for bagging two world-class awards. The EP8 Ultra AI-powered video doorbell won the European Product Design Award 2026 (EPDA 2026), keeping leading in user-centric AI. Meanwhile, the DL50FVX smart lock was named the 2026 Golden Pin Design Award (GPDA) laureate for its intuitive access management and entered the finalist of the Best Design Awards. The growing prestige of EZVIZ’s smart home access management lineup marks a new chapter of providing living experiences with multi-level interaction, modern aesthetics, and emotional care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022441786/en/ Two representative models from EZVIZ's smart entry family take home prestigious awards for user-centric innovation. Founded in 2016, the EPDA aims to recognize well-thought-out products that break with tradition and improve everyday life. Continually refres
Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press Release
Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the company’s Injectable Aesthetics portfolio in China – one of the world's largest and fastest-growing aesthetics markets.8,9 This approval follows successful authorizations and launches of Relfydess in more than 35 markets worldwide. Relfydess is the first and only ready-to-use liquid neuromodulator developed with PEARL Technology, designed to deliver a highly active, innovative, complex-free molecule that addresses the real needs of patients and healthcare professionals.1,2,4,5 It is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time.1,10 At a time whenpatients and healthcare professionals are increasingly seeking high-performance neuromodulators that rapidly deliver long-lasting, natural-looking outcomes, Re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom